ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tambotatug pelitecan

Also written as “YL201”, “YL201 for Injection” and “Tambotatug pelitecan”.

Its studies are mostly in Small Cell Lung Carcinoma · Nasopharyngeal Carcinoma · Pancreatic Neoplasms · Esophageal Squamous Cell Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Drug pageTambotatug pelitecan: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 23, 202413 company-led studies, 13 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MediLink Therapeutics (Suzhou)1212 open or runningphase 3since Sep 23, 2024Jun 16, 2022Jan 2027phase 2 · NCT07208773
Amgenits history only11 open or runningphase 1since Mar 21, 2025Mar 21, 2025Jun 23, 2031phase 1 · NCT06898957
  • Named in hoffmann la roche’s own pipeline as RG6919 tambotatug pelitecan (MediLink), phase 1, as of Oct 22, 2026 (source).

Also a collaborator on its studies: Hoffmann-La Roche, Fosun Pharma and Akesobio.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of MediLink Therapeutics (Suzhou) only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 16, 2022First study: phase 2 study in Advanced Solid TumorFirst studyNCT05434234 · 312 planned · United States, Canada, China and more
  2. Sep 21, 2023Phase 2 study in Advanced Solid TumorNCT06057922 · 990 enrolled · China
  3. Jan 28, 2024Phase 2 study in Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT06241846 · 100 planned · China
  4. Apr 23, 2024Phase 1 study in Advanced Solid TumorsNCT06394414 · 187 enrolled · China
  5. Sep 23, 20242 phase 3 studiesNCT06612151, NCT06629597
  6. Jul 10, 2025Named tambotatug pelitecanINNProposed as its International Nonproprietary Name in WHO's List 133 · before, YL201
  7. Sep 28, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07208773 · 260 planned · China
  8. Nov 17, 2025Phase 2 study in RecurrenceNCT07258979 · 202 planned · China
  9. Feb 6, 2026Phase 2 study in Thoracic NeoplasmsNCT07407933 · 118 planned · United States, Belgium, France and more
  10. Mar 17, 2026Phase 3 study in Advanced Esophageal Squamous Cell CarcinomaNCT07487896 · 440 planned · China
  11. Jul 28, 2026Phase 3 study in SCLC, Extensive StageNCT07739758 · 442 planned · China
  12. Aug 31, 2026Phase 3 study in Pancreatic NeoplasmsNCT07803783 · 320 planned · China

Ahead

  1. Jan 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07208773
  2. Feb 2027Primary completion: phase 2 study in Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT06241846
  3. Apr 6, 2027Primary completion: phase 2 study in Advanced Solid TumorNCT05434234
  4. Apr 29, 2027Primary completion: phase 1 study in Advanced Solid TumorsNCT06394414

TargetBeta

“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) site-specifically conjugated to an as of yet undisclosed topoisomerase-1 inhibitor via a tumor protease-cleavable linker, with potential antineoplastic ac…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) site-specifically ”NCIt, by rule

Other programs on CD276

ProgramCompanyFurthest phaseStudies
risvutatug rezetecanHansoh Pharmaceutical Groupphase 330
ifinatamab deruxtecanMerckphase 316
Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043CSPC Pharmaceutical Groupphase 36
Anti-B7-H3 Antibody-drug Conjugate MHB088CruleMinghui Pharmaceuticalphase 34
Elfetabart DrozuntecanruleBioNTechphase 33
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruletj-biopharma-co-ltdphase 33
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01ruleradiopharm-theranostics-ltdphase 21
Autologous Anti-B7-H3 CAR T-cells BCB-276rulebrainchild-bio-incphase 21
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencorphase 12
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11
HLX316Fosun Pharmaphase 11

Studies

All 12 MediLink Therapeutics (Suzhou) leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07803783Pancreatic Neoplasms · China3Not yet recruitingJan 2029320
NCT07739758SCLC, Extensive Stage · China3RecruitingJun 2029442
NCT07487896Advanced Esophageal Squamous Cell Carcinoma · China3RecruitingApr 30, 2028440
NCT07407933Thoracic Neoplasms · United States, Belgium, France and more2RecruitingNov 2028118
NCT07258979Recurrence · China2RecruitingFeb 2028202
NCT07208773Carcinoma, Non-Small-Cell Lung · China2RecruitingJan 2027260
NCT06629597Nasopharyngeal Carcinoma · China3Active, not recruitingDec 1, 2027400
NCT06612151Small Cell Lung Carcinoma · China3Active, not recruitingDec 1, 2027438
NCT06394414Advanced Solid Tumors · China1Active, not recruitingApr 29, 2027187
NCT06241846Metastatic Castration-resistant Prostate Cancer (mCRPC) · China2RecruitingFeb 2027100
NCT06057922Advanced Solid Tumor · China2Active, not recruitingOct 2026990
NCT05434234Advanced Solid Tumor · United States, Canada, China and more2RecruitingApr 6, 2027312

How it is read

Names in the registry

  • “YL201”, 11 entries
  • “YL201 for Injection”, 2 entries
  • “Tambotatug pelitecan”, 1 entry
  • “YL201 and atezolizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.